Gilead reports results from Phase 3 studies of switching to Descovy-based regimens from Truvada-based regimens

Gilead Sciences has reported 96-week data from a Phase 3 study and 48-week data from two Phase 3b studies analysing the safety and efficacy of switching virologically suppressed HIV-1 infected patients from regimens containing Truvada to regimens con …

Source: Drug Development Technology - October 25, 2016 Category: Pharmaceuticals Source Type: news